Amit Mehta, MD

Amit Mehta, MD, outlines the common toxicities encountered with immunotherapy-containing regimens in urothelial cancer and strategies to mitigate them.

Amit Mehta, MD, discusses practice-changing urothelial carcinoma data that have been presented throughout 2024 and 2025.

A panel of experts discuss the future of R/R DLBCL treatment and review some recent data from the 2022 ASH meeting.

Experts discuss the potential use of CAR T-cell therapy in the front line setting as well as reviewing the use of tafasitamab from the FRONT-MIND and FIRST-MIND trials.

Insightful discussion among a panel of oncologists on how to best sequence therapies for patients with R/R DLBCL.

Experts review some of the safety outcomes from the ZUMA-7 trial as well as discussing the clinical implications of the ZUMA-7 trial into their practice.

An overview of the ZUMA-7 and the TRANSFORM trial as well as reviewing eligibility criteria for patients who might receive CAR-T therapy.

Panel of experts discuss where CAR T-cell therapy might fit into the treatment landscape for patients with R/R DLBCL.

Comprehensive insight into the L-MIND trial including a review of efficacy outcomes as well as discussing the implications of the data into clinical practice.

Experts discuss which factors are considered when choosing treatment options for patients with R/R DLBCL as well as reviewing the mechanism of tafasitamab.

Insightful discussion among experts into a brief overview of relapsed/refractory DLBCL (R/R DLBCL).

Expert oncologists provide a brief overview of front-line treatment options for patients diagnosed with double large b-cell lymphoma (DLBCL).